Elironrasib clinical trials
Elironrasib is named as an intervention in 4 current clinical trials in our USA, France, Spain, Italy, Germany, Netherlands, Czechia, South Korea, Taiwan, Australia, Denmark, Austria, Poland and Singapore registers. 3 are recruiting patients now. The most common phase is Phase 1/2. The lead sponsor is Revolution Medicines, Inc. The most-studied condition is Non-Small Cell Lung Cancer (NSCLC). The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial, 1 with a site in Ireland.
Patient leaflets for Elironrasib
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Elironrasib
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Elironrasib in the EU trials register (CTIS)
1 trial · 1 in IrelandAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Elironrasib. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
2025-524623-50-00 · Neoplasms
|
Phase 1 | Ongoing | Revolution Medicines Inc | Ireland + 8 more |
Conditions studied with Elironrasib
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Non-Small Cell Lung Cancer (NSCLC) | 2 |
| Pancreatic Ductal Adenocarcinoma | 2 |
| Advanced Solid Tumors | 1 |
| Metastatic Solid Tumors | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
| NSCLC | 1 |
| Colorectal Cancer | 1 |
| Non-Small Cell Lung Cancer, NSCLC | 1 |
| KRAS, NRAS, HRAS-mutated NSCLC | 1 |
| KRAS G12C-mutated Solid Tumors, Lung Cancer | 1 |
| Lung Cancer Stage IV, Advanced Solid Tumor, Cancer | 1 |
| Colorectal Cancer (CRC) | 1 |
| Advanced Solid Tumor | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Revolution Medicines, Inc | 4 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Elironrasib trials
How many clinical trials are testing Elironrasib?
4 current trials in our USA, France, Spain, Italy, Germany, Netherlands, Czechia, South Korea, Taiwan, Australia, Denmark, Austria, Poland and Singapore registers name Elironrasib (also registered as RMC-6291) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Elironrasib trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 3 with sites in USA, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Germany, 2 with sites in Netherlands, 1 with sites in Czechia, 1 with sites in South Korea, 1 with sites in Taiwan, 1 with sites in Australia, 1 with sites in Denmark and 1 with sites in Austria. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Elironrasib clinical trials?
The lead sponsor is Revolution Medicines, Inc. The number in brackets is how many trials each organisation leads.
Are there Elironrasib clinical trials in Ireland?
Yes. 1 trial in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Elironrasib works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Elironrasib works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Elironrasib (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.